For primary AML leukaemia blast with FLT3/ITD mutation, CD44v6 CAR‐T presented significant anti‐leukaemia effects but no obvious killing to the healthy donor, indicating the safety of normal myeloid cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.